Role of surgery in ovarian carcinoma

被引:138
作者
Fader, Amanda Nickles [1 ]
Rose, Peter G. [1 ]
机构
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
关键词
D O I
10.1200/JCO.2007.11.0932
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Surgery plays a critical role in the optimal management of all stages of ovarian carcinoma. In apparent early-stage ovarian cancer, a comprehensive surgical evaluation allows stratification of patients into low- and high-risk categories. Low-risk patients may be candidates for fertility-sparing surgery and can safely avoid chemotherapy and be observed. Treatment of patients with high-risk early-or advanced-stage ovarian cancer usually requires a combined modality approach. Although it is well known that epithelial ovarian cancer is moderately chemosensitive, what distinguishes it most from other metastatic solid tumors is that surgical cytoreduction of tumor volume is highly correlated with prolongation of patient survival. Procedures such as radical pelvic surgery, bowel resection, and aggressive upper abdominal surgery are commonly required to achieve optimal cytoreduction. Women who develop recurrent disease may be eligible for a secondary cytoreductive surgery or may require a surgical intervention to palliate disease-related symptoms. For women at high risk of ovarian cancer, prophylactic bilateral salpingo-oophorectomy significantly reduces the incidence of this disease. The purpose of this article is to provide a comprehensive review of the surgical management of ovarian carcinoma. The roles of primary, interval, and secondary cytoreductive surgeries; second-look procedures; and palliative surgery are reviewed. The indications for fertility-sparing and minimally invasive surgery as well as the current guidelines for prophylactic surgery in high-risk mutation carriers are also discussed.
引用
收藏
页码:2873 / 2883
页数:11
相关论文
共 156 条
  • [61] GRIFFITHS CT, 1975, NATL CANCER I MONOGR, P101
  • [62] Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum
    Gronlund, B
    Lundvall, L
    Christensen, IJ
    Knudsen, JB
    Hogdall, C
    [J]. EJSO, 2005, 31 (01): : 67 - 73
  • [63] ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes
    Guillem, Jose G.
    Wood, William C.
    Moley, Jeffrey F.
    Berchuck, Andrew
    Karlan, Beth Y.
    Mutch, David G.
    Gagel, Robert F.
    Weitzel, Jeffrey
    Morrow, Monica
    Weber, Barbara L.
    Giardiello, Francis
    Rodriguez-Bigas, Miguel A.
    Church, James
    Gruber, Stephen
    Offit, Kenneth
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) : 4642 - 4660
  • [64] The role of secondary cytoreductive surgery for recurrent ovarian cancer
    Güngör, M
    Ortaç, F
    Arvas, M
    Kösebay, D
    Sönmezer, M
    Köse, K
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 97 (01) : 74 - 79
  • [65] HACKER NF, 1983, OBSTET GYNECOL, V61, P413
  • [66] ADVANCED OVARIAN-CANCER - LONG-TERM RESULTS OF TREATMENT WITH INTENSIVE CISPLATIN-BASED CHEMOTHERAPY OF BRIEF DURATION
    HAINSWORTH, JD
    GROSH, WW
    BURNETT, LS
    JONES, HW
    WOLFF, SN
    GRECO, FA
    [J]. ANNALS OF INTERNAL MEDICINE, 1988, 108 (02) : 165 - 170
  • [67] Cytoreductive surgery for recurrent ovarian cancer
    Hauspy, Jan
    Covens, Allan
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2007, 19 (01) : 15 - 21
  • [68] HAVLIK RJ, 1994, CANCER, V74, P2101, DOI 10.1002/1097-0142(19941001)74:7+<2101::AID-CNCR2820741718>3.0.CO
  • [69] 2-M
  • [70] Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: Implications regarding surgical management
    Hoffman, MS
    Griffin, D
    Tebes, S
    Cardosi, RJ
    Martino, MA
    Fiorica, JV
    Lockhart, JL
    Grendys, EC
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (02) : 582 - 586